Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2014) 3 OC6.4 | DOI: 10.1530/boneabs.3.OC6.4

Osteoporosis treatment and the effects of physical activity

Long-term denosumab therapy further reduces the rate of non-vertebral fractures in women with persisting low hip BMD after 3 years

S Ferrari1, JD Adachi2, K Lippuner3, C Zapalowski4, PD Miller5, J-Y Reginster6, O Törring7, DL Kendler8, N Daizadeh4, A Wang4, CD O’Malley4, RB Wagman4, C Libanati4 & EM Lewiecki9


1Geneva University Hospital, Geneva, Switzerland; 2McMaster University, Hamilton, Ontario, Canada; 3Bern University Hospital, Bern, Switzerland; 4Amgen Inc., Thousand Oaks, California, USA; 5Colorado Center for Bone Research, Lakewood, Colorado, USA; 6University of Liège, Liège, Belgium; 7Karolinska Institutet, Södersjukhuset, Stockholm, Sweden; 8University of British Columbia, Vancouver, British Columbia, Canada; 9New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico, USA.

Objective: Evidence for further reduction of nonvertebral fracture (NVFX) beyond 3 years of antiresorptive therapy is limited. Since long-term denosumab (DMAb) treatment is associated with continuous increases in BMD and sustained fracture reduction, we analyzed the influence of femoral neck (FN) BMD after 3 years on NVFX rates.

Methods: Long-term subjects received 7 continuous years of DMAb; cross-over subjects received 3 years of placebo (FREEDOM) and 4 years of DMAb (extension). NVFX rates for years 1–3 vs the 4th year of DMAb were compared in each group separately and combined, and for subgroups defined by FN BMD T-score after 3 years of DMAb treatment. Adjusted rate ratios (RR) (95% CIs) between observational periods were computed by GEE Poisson regression.

Results: For long-term subjects, the NVFX rate was 1.98/100 subject-years during years 1–3 of DMAb treatment vs 1.43 (RR(95%CI)=0.73(0.50–1.06)) during year 4 and 1.45 (RR(95%CI)=0.74(0.59–0.95)) during years 4–7. For cross-over subjects, the NVFX rate was 2.20 during years 1–3 of DMAb vs 1.03 (RR(95%CI)=0.48(0.29–0.79)) in year 4. In the combined groups (n=4073) the rate was 2.08 during years 1–3 of DMAb and 1.27(RR(95%CI)=0.62(0.46–0.83)) in year 4. Compared with the first 3 years of treatment, the greatest reduction in NVFX in year 4 was observed in subjects with FN T-scores ≤−2.5 (n=778; RR(95%CI)=0.39(0.19–0.80)). A further reduction in NVFX was also present, but less pronounced, in subjects with T-scores >−2.5 and <−1.0 (n=2407; RR(95%CI)=0.69(0.47–1.01)), but not in subjects with T-scores ≧−1.0.

Conclusion: Continued DMAb treatment beyond 3 years was associated with further reductions in NVFX rates, particularly in women whose BMD remained low after 3 years of treatment. These data suggest it may be possible to identify a BMD value below which ongoing treatment will have maximum fracture reduction benefit.

Volume 3

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.